ClinicalTrials.gg
CompletedNCT07712705Updated Aug 3, 2026

HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

A Phase 3 interventional study of HPP737 and Placebo matching HPP737 in Psoriasis, sponsored by Newsoara Biopharma Co., Ltd.. Completed at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Newsoara Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.
  • Registered 3 years 2 months after the study started (first participant enrolled Apr 2023, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
26th of 182
515 · median 171
Started
2023
with 27 others
Phase 3
58 of 206
16 open now
Registered
197th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 26th largest by enrollment of the 182 interventional ones that give a count, is one of 28 that started in 2023, is one of 58 in phase 3, and was the 197th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are:

Does drug HPP737 improve psoriasis severity compared to a placebo at Week 16, as measured by the proportion of patients achieving a significant reduction in the Psoriasis Area and Severity Index (PASI) score? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to a placebo (a look-alike substance that contains no drug) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. Participants will:

Take drug HPP737 or a placebo orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools, including the Psoriasis Area and Severity Index (PASI), static Physician's Global Assessment (sPGA), and Body Surface Area (BSA) Eligible participants are adults aged 18 years and older with a confirmed diagnosis of chronic plaque psoriasis for at least 6 months and moderate-to-severe disease at screening.

Read the detailed description

HPP737-Psoriasis-301 is a phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy and safety of oral HPP737 in adult patients with moderate-to-severe plaque psoriasis. The study is sponsored by Newsoara Biopharma Co., Ltd. The trial involves approximately 504 patients across multiple centers nationwide.

HPP737 is a novel, potent, orally administered, and selective phosphodiesterase type 4 (PDE4) inhibitor. PDE4 is a validated therapeutic target for inflammatory diseases including psoriasis. By inhibiting PDE4, HPP737 raises intracellular cyclic adenosine monophosphate (cAMP) levels, thereby exerting broad anti-inflammatory effects. Preclinical and clinical data have demonstrated that HPP737 potently inhibits interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-α) production both in vitro and in vivo. Notably, HPP737 has shown a favorable safety and tolerability profile in phase I studies, with no dose-limiting gastrointestinal side effects-such as nausea, vomiting, or diarrhea-commonly associated with other PDE4 inhibitors.

This is a randomized, double-blind, placebo-controlled, parallel-group trial. Eligible patients are adults aged ≥18 years with a confirmed diagnosis of stable chronic plaque psoriasis for ≥6 months and moderate-to-severe disease at screening, defined by Psoriasis Area and Severity Index (PASI) score ≥12, static Physician's Global Assessment (sPGA) score ≥3, and body surface area (BSA) involvement ≥10%. Patients are randomized in a 1:1:1 ratio to one of three treatment arms: HPP737 10 mg once daily, HPP737 20 mg once daily, or placebo.

The total treatment duration is 52 weeks, divided into two phases:

Core Phase (Weeks 0-16): Patients receive double-blind treatment with HPP737 10 mg, HPP737 20 mg, or placebo.

Extension Phase (Weeks 16-52): Patients who complete the core phase enter the extension phase. Those originally assigned to placebo are switched to HPP737 20 mg; patients in the HPP737 10 mg and 20 mg groups continue on their assigned doses without adjustment.

The primary objective is to evaluate the efficacy of HPP737 compared with placebo at Week 16 in patients with moderate-to-severe plaque psoriasis. Secondary objectives include: (1) evaluation of additional efficacy characteristics of HPP737 versus placebo; (2) assessment of the safety of HPP737 in patients with moderate-to-severe chronic plaque psoriasis; and (3) evaluation of population pharmacokinetic (PPK) characteristics of HPP737 in this patient population.

The study is conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Moderate-to-severe plaque psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily sign the form before initiation of any study-related procedures, are able to communicate effectively with investigators, and understand and comply with all requirements of this study;
  • Age at signing informed consent: age ≥18 years, regardless of gender;
  • Diagnosed with a history of chronic plaque psoriasis (Psoriasis vulgaris) and disease stability for ≥6 months prior to screening;
  • Diagnosed with moderate to severe plaque psoriasis (Psoriasis vulgaris), and at screening meets the following requirements: 1) PASI (Psoriasis Area and Severity Index) score ≥ 12; and 2) Static Physician Global Assessment (sPGA) score ≥ 3; and 3) Body Surface Area (BSA) involvement ≥ 10%;
  • (BMI): 18 kg/m2 ≤ BMI ≤ 35 kg/m2

Exclusion criteria

Exclusion Criteria:

  • At screening, diagnosis of psoriasis types other than chronic plaque psoriasis (Psoriasis vulgaris), e.g., pustular psoriasis (Psoriasis pustulosa), erythrodermic psoriasis (Psoriasis erythrodermica), and guttate psoriasis (Psoriasis guttata);
  • Patients with drug-induced psoriasis (including but not limited to new-onset or exacerbation of psoriasis caused by β-blockers [beta-blockers], calcium channel inhibitors [calcium channel blockers], or lithium preparations [lithium salts]);
  • Subjects have other skin diseases that may interfere with clinical assessment (e.g., bacterial, fungal, or viral skin infections, seborrheic dermatitis), chronic diarrhea, severe digestive diseases (such as active gastric ulcer, gastrointestinal tract disorders), or history of inflammatory bowel disease (Crohn's disease, ulcerative colitis), or other active inflammatory diseases (mixed connective tissue disease, idiopathic inflammatory myopathy); Note: Chronic diarrhea is defined as disease course >4 weeks, or recurrent diarrhea in a 2-4 week interval. Diarrhea refers to defecation significantly exceeding usual frequency (>3 times/day), stool consistency is loose, water content (>85%), and stool may contain mucus, pus, blood, or undigested food.
  • History of congenital or acquired immunodeficiency;
  • Severe infection or systemic infection within 4 weeks prior to randomization requiring oral and/or intravenous antimicrobial treatment, or hospitalization due to infection;
  • At screening, subject's history, symptoms, and examination results indicate active tuberculosis;
  • History of moderate-to-severe heart failure ( [NYHA] functional classification ≥ Class 3), or occurrence of cardiovascular or cerebrovascular events or severe events within 3 months prior to randomization, such that investigators consider these subjects unsuitable for participation in this clinical trial;
  • History of in any organ system within 5 years prior to randomization, except for malignancies with low risk of and mortality, such as adequately treated carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin;
  • Subjects with a history of depression and/or, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) during the screening and baseline period, with ideation or any behavior (see Appendix 6). Subjects who answer "yes" to any question on the C-SSRS questionnaire, or those deemed at risk by the investigator's clinical judgment, will be excluded;
  • Presence of , progressive, or uncontrolled disease during the screening period, including but not limited to respiratory, cardiovascular, endocrine, hematologic, skeletal, or neurologic systems, as assessed by the investigator to pose unacceptable risk for participation or interfere with data interpretation;
  • Prior to screening, use of the following psoriasis treatment modalities/drugs: 1) Received topical treatment for psoriasis within 2 weeks prior to randomization, such as , vitamin D3 derivatives, retinoids, etc.; however, the subject is permitted to use the following topical treatments: non-medicated shampoos and emollients (i.e., those not containing glucocorticoids or vitamin D3 derivatives); Received phototherapy/photochemotherapy (including but not limited to psoralen plus ultraviolet A [PUVA] therapy, ultraviolet B [UVB]), or non-biological systemic therapy (including but not limited to systemic glucocorticoids, leflunomide, cyclophosphamide, azathioprine, methotrexate, cyclosporine, retinoids, mycophenolate mofetil, traditional Chinese medicine for the treatment of psoriasis, or other small-molecule targeted agents for the treatment of psoriasis) within 4 weeks prior to randomization; Tumor necrosis factor-alpha (TNF-α) antagonist: (1) The patient has used at least one TNF-α antagonist within the specified time period prior to randomization (for example, adalimumab, infliximab, golimumab, etanercept, or certolizumab pegol within 12 weeks prior to randomization); (2) or the patient has used two or more TNF-α antagonists prior to randomization; 4) Used other biologic agents within 24 weeks prior to randomization, including but not limited to anti-interleukin-17 (anti-IL-17) inhibitors, anti-interleukin-23 (anti-IL-23) inhibitors, anti-interleukin-12/interleukin-23 (anti-IL-12/23) inhibitors, and related agents;
  • Receipt of within 12 weeks prior to randomization, or planned vaccination with live attenuated vaccines during the study period;
  • Subjects who have previously used other PDE4 inhibitors (such as apremilast, Hemay005, etc.);
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
515 participants (actual)

Study arms

  • Experimental
    HPP737 10 mg

    Specification: 10 mg Dosage and Administration: Two capsules (one with 10 mg HPP737 and one with 10 mg placebo) are administered orally once daily for a total duration of 52 weeks.

    Drug: HPP737

  • Experimental
    HPP737 20 mg

    Specification: 10 mg Dosage and Administration: Two capsules (two with 10 mg HPP737) are administered orally once daily for a total duration of 52 weeks.

    Drug: HPP737

  • Placebo comparator
    Placebo (cross over to HPP737 20mg at Week 17)

    Specification: 10 mg Administration and dosage: Two capsules (two with 10 mg placebo) are administered orally once daily for a total duration of 16 weeks. Then patients will be crossed over to receive HPP737 20 mg once daily starting at Week 17 and continuing through Week 52.

    Drug: HPP737 · Drug: Placebo matching HPP737

Interventions

  • DrugHPP737

    HPP737 capsule for oral administration

  • DrugPlacebo matching HPP737

    Placebo capsules matching HPP737 for oral administration

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. To evaluate the proportion of subjects who achieve PASI 75 (a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )from baseline to Week 16

    Time frame: From enrollment to end of treatment at 16 weeks

Secondary outcomes

  1. To evaluate the proportion of subjects who achieve a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) and who have a reduction of ≥2 points from baseline to Week 16.

    Time frame: From enrollment to end of treatment at 16 weeks

  2. To evaluate the proportion of subjects who achieve PASI 75 (a ≥ 75% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )from baseline to Week 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks

  3. To evaluate the proportion of subjects who achieve PASI 50 (a ≥ 50% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )at Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  4. To evaluate the proportion of subjects who achieve PASI 90 (a ≥ 90% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )from baseline to Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  5. To evaluate the proportion of subjects who achieve PASI 100 (a ≥ 100% reduction (improvement) in the Psoriasis Area and Severity Index (PASI) score )from baseline to Week 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  6. To evaluate the change from baseline in PASI(Psoriasis Area and Severity Index) score and the percent change from baseline at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  7. To evaluate the proportion of subjects who achieve a sPGA score of 0 (clear) or 1 (almost clear) and who have a reduction of ≥2 points from baseline at Week 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  8. To evaluate the change from baseline in BSA and the percent change from baseline at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  9. To evaluate the change from baseline in DLQI and the percent change from baseline at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

    Time frame: From enrollment to end of treatment at 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 weeks.

  10. To evaluate the incidence and severity of adverse events.

    Number and percentage of participants with treatment-emergent adverse events (TEAEs), graded by severity according to CTCAE 5.0.

    Time frame: From ICF signed to end of study follow-up (at 54 weeks).

  11. To evaluate the pharmacokinetic profile (including plasma concentrations and derived parameters) over time at Weeks 0, 2, 4, 8, and 12.

    Time frame: From enrollment to end of treatment at 2,4,8,12 weeks

07

Study locations

50 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, China
  • Peking University People's Hospital
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
  • Cangzhou People's Hospital
    Cangzhou, China
  • The Second Hospital of Jilin University
    Changchun, China
  • The Second Xiangya Hospital of Central South University
    Changsha, China
  • The Third Xiangya Hospital of Central South University
    Changsha, China
  • Xiangya Hospital, Central South University
    Changsha, China
  • Affiliated Hospital of Chengde Medical College
    Chengde, China
  • Chengdu Second People's Hospital
    Chengdu, China
  • Dongguan First People's Hospital
    Dongguan, China
  • Shengli Oilfield Central Hospital
    Dongying, China
  • The First Affiliated Hospital of Gannan Medical University
    Gannan, China
  • Dermatology Hospital, Southern Medical University
    Guangzhou, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • The Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, China
  • The Third Affiliated Hospital of Sun Yat-sen University
    Guangzhou, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, China
  • Shandong Provincial Hospital of Dermatology
    Guiyang, China
  • Hangzhou First People's Hospital
    Hangzhou, China
  • Hangzhou Third People's Hospital
    Hangzhou, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, China
  • Jiaxing First Hospital
    Jiaxing, China
  • Jinan Central Hospital
    Jinan, China
  • Shandong Provincial Hospital of Dermatology
    Jinan, China
  • Shandong Provincial Hospital
    Jinan, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, China
  • The First People's Hospital of Lianyungang
    Lianyungang, China
  • Jiangxi Provincial Dermatology Hospital
    Nanchang, China
  • Nanyang Central Hospital
    Nanyang, China
  • Nanyang First People's Hospital
    Nanyang, China
  • Shanghai Skin Disease Hospital
    Shanghai, China
  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM
    Shanghai, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, China
  • Shiyan People's Hospital
    Shiyan, China
  • Suining Central Hospital
    Suining, China
  • Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine
    Tianjin, China
  • Wuhan First Hospital
    Wuhan, China
  • Yijishan Hospital of Wannan Medical College
    Wuhu, China
  • Jiangyin Hospital of Traditional Chinese Medicine
    Wuxi, China
  • Wuxi Second People's Hospital
    Wuxi, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, China
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, China
  • Xianyang Hospital of Yan'an University
    Xianyang, China
  • Yancheng No.1 People's Hospital
    Yancheng, China
  • Yantai Yuhuangding Hospital
    Yantai, China
  • General Hospital of Ningxia Medical University
    Yinchuan, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2023, 5 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 17, 2026
StartActual
Apr 20, 2023
Primary completionActual
Sep 29, 2023
CompletionActual
Feb 20, 2025
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07712705
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Apr 20, 2023
Primary completion
Sep 29, 2023
Completion
Feb 20, 2025
Last update
Aug 3, 2026

Study contacts

Jianzhong Zhang
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HPP737

Start the discussion